Blocking MHC class II on human endothelium mitigates acute rejection

JCI Insight

Volumn 1, Issue 1, 2016, Pages

  Abrahimi, Parwiz ^a   Qin, Lingfeng ^a   Chang, William G ^a   Bothwell, Alfred L M ^a   Tellides, George ^a   Saltzman, W Mark ^b   Pober, Jordan S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84983738952     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.85293     Document Type: Article

References (61)

1. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med. 1994; 331(6):365-376.
2. Stehlik J, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report - 2011. J Heart Lung Transplant. 2011; 30(10):1078-1094.
3. Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report - 2009. J Heart Lung Transplant. 2009; 28(10):1007-1022.
4. Colvin RB, et al. Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol. 1997; 8(12):1930-1941.
5. Strehlau J, et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci U S A. 1997; 94(2):695-700.
6. Lakkis FG, Lechler RI. Origin and biology of the allogeneic response. Cold Spring Harb Perspect Med. 2013; 3(8):a014993.
7. Heeger PS, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol. 1999; 163(4):2267-2275.
8. Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol. 2006; 24:519-540.
9. Makhlouf L, et al. Allorecognition and effector pathways of islet allograft rejection in normal versus nonobese diabetic mice. J Am Soc Nephrol. 2003; 14(8):2168-2175.
10. Shiao SL, McNiff JM, Pober JS. Memory T cells and their costimulators in human allograft injury. J Immunol. 2005; 175(8):4886-4896.
11. Weaver TA, et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med. 2009; 15(7):746-749.
12. Pearl JP, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant. 2005; 5(3):465-474.
13. Jutte NH, et al. Human heart endothelial-cell-restricted allorecognition. Transplantation. 1996; 62(3):403-406.
14. Adams PW, et al. Alloantigenicity of human endothelial cells. 1. Frequency and phenotype of human T helper lymphocytes that can react to allogeneic endothelial cells. J Immunol. 1992; 148(12):3753-3760.
15. Shiao SL, Kirkiles-Smith NC, Shepherd BR, McNiff JM, Carr EJ, Pober JS. Human effector memory CD4+ T cells directly recognize allogeneic endothelial cells in vitro and in vivo. The Journal of Immunology. 2007; 179(7):4397-4404.
16. Brewer Y, et al. Effect of graft perfusion with two CD45 monoclonal antibodies on incidence of kidney allograft rejection. Lancet. 1989; 2(8669):935-937.
17. Salvadori M, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant. 2006; 6(12):2912-2921.
18. Biedermann BC, Pober JS. Human vascular endothelial cells favor clonal expansion of unusual alloreactive CTL. J Immunol. 1999; 162(12):7022-7030.
19. Biedermann BC, Pober JS. Human endothelial cells induce and regulate cytolytic T cell differentiation. J Immunol. 1998; 161(9):4679-4687.
20. Dengler TJ, Pober JS. Human vascular endothelial cells stimulate memory but not naive CD8+ T cells to differentiate into CTL retaining an early activation phenotype. J Immunol. 2000; 164(10):5146-5155.
21. Murray AG, et al. Dermal microvascular injury in the human peripheral blood lymphocyte reconstituted-severe combined immunodeficient (HuPBL-SCID) mouse/skin allograft model is T cell mediated and inhibited by a combination of cyclosporine and rapamycin. Am J Pathol. 1998; 153(2):627-638.
22. Kreisel D, et al. Vascular endothelium does not activate CD4+ direct allorecognition in graft rejection. J Immunol. 2004; 173(5):3027-3034.
23. Lorber MI, et al. Human allogeneic vascular rejection after arterial transplantation and peripheral lymphoid reconstitution in severe combined immunodeficient mice1. Transplantation. 1999; 67(6):897-903.
24. Rao DA, et al. Interleukin (IL)-1 promotes allogeneic T cell intimal infiltration and IL-17 production in a model of human artery rejection. J Exp Med. 2008; 205(13):3145-3158.
25. Yi T, et al. Reperfusion injury intensifies the adaptive human T cell alloresponse in a human-mouse chimeric artery model. Arterioscler Thromb Vasc Biol. 2012; 32(2):353-360.
26. Nadig SN, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med. 2010; 16(7):809-813.
27. Yacoub-Youssef H, et al. Chronic vascular rejection: histologic comparison between two murine experimental models. Transplant Proc. 2005; 37(6):2886-2887.
28. Pober JS, Tellides G. Participation of blood vessel cells in human adaptive immune responses. Trends Immunol. 2012; 33(1):49-57.
29. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007; 7(2):118-130.
30. Hirschberg H, Braathen LR, Thorsby E. Antigen presentation by vascular endothelial cells and epidermal Langerhans cells: the role of HLA-DR. Immunol Rev. 1982; 66(1):57-77.
31. Epperson DE, Pober JS. Antigen-presenting function of human endothelial cells. Direct activation of resting CD8 T cells. J Immunol. 1994; 153(12):5402-5412.
32. Chang CH, Fontes JD, Peterlin M, Flavell RA. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J Exp Med. 1994; 180(4):1367-1374.
33. Steimle V, Siegrist C-A, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA. Science. 1994; 265(5168):106-109.
34. Masternak K, Reith W. Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation. EMBO J. 2002; 21(6):1379-1388.
35. Boss JM, Jensen PE. Transcriptional regulation of the MHC class II antigen presentation pathway. Curr Opin Immunol. 2003; 15(1):105-111.
36. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper a T-killer cell. Nature. 1998; 393(6684):474-478.
37. Moriggl R, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 1999; 10(2):249-259.
38. Abrahimi P, et al. Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9. Circ Res. 2014; 117(2):121-128.
39. Zheng L, Gibson TF, Schechner JS, Pober JS, Bothwell AL. Bcl-2 transduction protects human endothelial cell synthetic microvessel grafts from allogeneic T cells in vivo. J Immunol. 2004; 173(5):3020-3026.
40. Suárez Y, Shepherd BR, Rao DA, Pober JS. Alloimmunity to human endothelial cells derived from cord blood progenitors. J Immunol. 2007; 179(11):7488-7496.
41. Lafferty KJ, Bootes A, Dart G, Talmage DW. Effect of organ culture on the survival of thyroid allografts in mice. Transplantation. 1976; 22(2):138-149.
42. Lakkis FG, Arakelov A, Konieczny BT, Inoue Y. Immunologic 'ignorance'of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med. 2000; 6(6):686-688.
43. Meehan SM, et al. Cytotoxicity and apoptosis in human renal allografts: identification, distribution, and quantitation of cells with a cytotoxic granule protein GMP-17 (TIA-1) and cells with fragmented nuclear DNA. Lab Invest. 1997; 76(5):639-649.
44. Racusen LC, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999; 55(2):713-723.
45. Hirsch HH, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005; 79(10):1277-1286.
46. Haas M, Kraus ES, Samaniego-Picota M, Racusen LC, Ni W, Eustace JA. Acute renal allograft rejection with intimal arteritis: histologic predictors of response to therapy and graft survival. Kidney Int. 2002; 61(4):1516-1526.
47. Gaber LW, et al. Correlation between Banff classification, acute renal rejection scores and reversal of rejection. Kidney Int. 1996; 49(2):481-487.
48. Ponticelli C, et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients1, 2. Transplantation. 2001; 72(7):1261-1267.
49. Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D. Sequential protocols using basiliximab versus anti-thymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation. 2004; 78(4):584-590.
50. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006; 355(19):1967-1977.
51. Hosgood SA, Heurn E, Nicholson ML. Normothermic machine perfusion of the kidney: better conditioning and repair? Transpl Int. 2015; 28(6):657-664.
52. Abrahimi P, Liu R, Pober J. Blood vessels in allotransplantation. Am J Transplant. 2015; 15(7):1748-1754.
53. Wang C, et al. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. J Clin Invest. 2013; 123(4):1677-1693.
54. Feng G, et al. Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection. Sci Transl Med. 2011; 3(83):83ra40.
55. Cypel M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011; 364(15):1431-1440.
56. St Peter SD, Imber CJ, Lopez I, Hughes D, Friend PJ. Extended preservation of non-heart-beating donor livers with normothermic machine perfusion. Br J Surg. 2002; 89(5):609-616.
57. Devalliere J, et al. Sustained delivery of proangiogenic microRNA-132 by nanoparticle transfection improves endothelial cell transplantation. FASEB J. 2014; 28(2):908-922.
58. Dahlman JE, et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat Nanotechnol. 2014; 9(8):648-655.
59. Shepherd BR, Enis DR, Wang F, Suarez Y, Pober JS, Schechner JS. Vascularization and engraftment of a human skin substitute using circulating progenitor cell-derived endothelial cells. FASEB J. 2006; 20(10):1739-1741.
60. Manes TD, Shiao SL, Dengler TJ, Pober JS. TCR signaling antagonizes rapid IP-10-mediated transendothelial migration of effector memory CD4+ T cells. J Immunol. 2007; 178(5):3237-3243.
61. Kummerow C, Schwarz EC, Bufe B, Zufall F, Hoth M, Qu B. A simple, economic, time-resolved killing assay. Eur J Immunol. 2014; 44(6):1870-1872.